Study of the Angiogenesis by PET/CT in Patients With Lymphoma
NCT ID: NCT02490891
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
21 participants
INTERVENTIONAL
2015-11-13
2020-10-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861
Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT
NCT00256490
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
NCT02317393
Detection and Characterization of Residual Masses in Lymphomas
NCT02300402
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
NCT04464590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Overall survival and disease free survival will be monitored during 18 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PET scan with RGD K5 imaging
PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
RGD K5 PET scan
PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RGD K5 PET scan
PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years old
* OMS ≤ 1
* Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype
* Presence of measurable tumor with at least a node mass superior to 3 centimeters
* Stage I to IV
* Inform consent signed
Exclusion Criteria
* Absence of fixing on FDG-PET exam
* Pregnant , child bearing, breast feeding or without effective contraception method woman
* Hypersensitivity to RGD-K5
* Hypersensitivity to FDG
* Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter)
* Neoplastic disease (less than 2 years or in progression)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Henri Becquerel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Vera, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Henri Becquerel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Henri Becquerel
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHB14.02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.